A notable finding is the significant reduction in CK-18 levels observed in highly adherent participants; this reduction was more pronounced after 6 and 24 months of intervention, with some impact likely due to the COVID-19 pandemic occurring between the 6- and 12-month sessions. The gene discussed is KRT18; the disease is COVID-19.